abc biopply - Preclinical Study Models and Services to De-Risk Drug Development
 |
The process for commercializing preclinically confirmed drugs currently has a success rate of only about 12%. |
 |
abc biopply is a specialist for advanced solutions in preclinical disease models and drug discovery. The company has pioneered a unique portfolio of 3D tissue imaging and analysis assays enabling the easy and reliable generation of quantitative datasets from tissues and cells. Based on the proprietary 3D CoSeedis™ multi-organoid technology the company has boosted the relevance of in vitro testing to the ex vivo level. |
 |
The related CRO services support pharmaceutical and biotech companies to improve the predictiveness of their preclinical models and to de-risk their drug discovery processes. |
Advantages at a glance
- Advanced predictiveness of preclinical disease models and drug development
- Provide excellent measurement quality of the conditions of environmentally-mediated drug resistance
- Enabling a rapid pre-selection of compounds
- abc biopply in-chip study models fully comply with FDA requirements for a micro physiological system
- Elimination of discovery load in traditional animal models
- Time- and cost-efficient alternative to conventional variants
- 3R: enabling animal free testing
